Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors
The Oncologist · 08.05.2025 · 30 (5)
DOI: 10.1093/oncolo/oyaf017 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 11.05.2025. Verfasst von Ian Nykaza und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Sarcoidosis, Lymphadenopathy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Importance While new intrathoracic adenopathy in a patient with cancer can represent progression of disease, the differential diagnosis is broad. Sarcoid-like reactions (SLR) remain an underreported source of lymphadenopathy in patients treated with immune checkpoint inhibitors (ICI), with limited reports in patients with cancers other than melanoma.
Objective
To characterize SLRs among patients treated with ICI for advanced solid tumors.
Methods
Data were collected on the clinical, pathologic, and radiographic presentation of patients treated with ICI who developed clinical or imaging findings suggestive of an SLR, including the presence of hilar or mediastinal lymphadenopathy, cutaneous/subcutaneous involvement, and/or worsening of existing sarcoidosis on ICI.
Results
Twelve patients were identified as having experienced an SLR. While 6 patients had melanoma, SLRs were also observed among patients with lung, gynecologic, and genitourinary cancers, including high-grade serous ovarian carcinoma, and an angiomyolipoma. Median time from initiation of ICI to diagnosis of an SLR was 3.4 months (range: 1.8-9.1). All but one patient (92%) were deemed to have had a radiographic response to ICI. Conclusions and relevance Clinicians should maintain the awareness of the possibility of SLRs in patients receiving ICI, particularly in patients whose scans show evidence of “mixed” response, with decreases in certain lesions coupled with new/increasing intrathoracic lymphadenopathy and/or other systemic signs of sarcoid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
- Department of Medicine, Weill Cornell Medical College, New York, NY 10065, United States.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
ORCID-Profile: Ian Nykaza, Alexander Drilon
Förderung
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- National Institutes of Health
- Memorial Sloan Kettering Cancer Center
Zitieren
APA
Nykaza, I., Murciano-Goroff, Y. R., Desilets, A., Harada, G., Postow, M. A., Callahan, M. K., Lee, C. H., Rudin, C. M., Kelsen, D. P., Stadler, Z. K., Wibmer, A. G., Hechtman, J. F., Drilon, A., & Friedman, C. F. (2025). Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors. The Oncologist, 30(5). https://doi.org/10.1093/oncolo/oyaf017
Vancouver
Nykaza I, Murciano-Goroff YR, Desilets A, Harada G, Postow MA, Callahan MK, et al. Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors. The Oncologist. 2025;30(5). doi:10.1093/oncolo/oyaf017
BibTeX
@article{Nykaza2025,
author = {Nykaza, Ian and Murciano-Goroff, Yonina R and Desilets, Antoine and Harada, Guilherme and Postow, Michael A and Callahan, Margaret K and Lee, Chung-Han and Rudin, Charles M and Kelsen, David Paul and Stadler, Zsofia K and Wibmer, Andreas G and Hechtman, Jaclyn F and Drilon, Alexander and Friedman, Claire F},
title = {Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {5},
doi = {10.1093/oncolo/oyaf017}
}
EUVIMED